Cinnarizin Sopharma
Cinnarizin Sopharma: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. Use in the elderly
- 12. Drug interactions
- 13. Analogs
- 14. Terms and conditions of storage
- 15. Terms of dispensing from pharmacies
- 16. Reviews
- 17. Price in pharmacies
Latin name: Cinnarizine Sopharma
ATX code: N07CA02
Active ingredient: cinnarizine (Cinnarizine)
Manufacturer: Sopharma, JSC (Sopharma, AD) (Bulgaria)
Description and photo update: 2020-07-04
Cinnarizine Sopharma is a drug used for disorders of peripheral and cerebral circulation, including vestibular disorders.
Release form and composition
The drug is produced in the form of tablets: biconvex, round (7 mm in diameter), almost white or white, odorless (50 pieces in a blister, 1 blister in a cardboard box and instructions for use of Cinnarizin Sopharma).
1 tablet contains:
- active substance: cinnarizine - 25 mg;
- additional components: wheat starch - 50.57 mg; lactose monohydrate - 63.12 mg; povidone K 25 - 5.66 mg; microcrystalline cellulose (type 101) - 3.85 mg; magnesium stearate - 1.03 mg; colloidal silicon dioxide - 0.77 mg.
Pharmacological properties
Pharmacodynamics
Cinnarizine belongs to the group of slow calcium channel blockers (BMCC). The drug helps to improve cerebral and peripheral blood circulation, suppressing the effect of a number of endogenous vasoconstrictors and the entry of calcium ions into cells by inhibiting slow voltage-gated calcium channels. The active substance demonstrates a vasodilating effect mainly on the cerebral vessels, without significantly affecting blood pressure (BP). The tool provides an increase in the elasticity of erythrocyte membranes, enhancing their ability to deform; lowers blood viscosity and increases muscle resistance to hypoxia. It has a moderate antihistamine activity, reduces the excitability of the vestibular apparatus, reduces the tone of the sympathetic nervous system.
Pharmacokinetics
In the gastrointestinal tract (GIT), cinnarizine is absorbed relatively slowly. After oral use, the maximum concentration (C max) of the active substance in the blood plasma is observed after 1-3 hours. The agent binds to plasma proteins by 80%, to erythrocytes by 13%, and is more intensively distributed in tissues for 4 hours after administration. In the liver, the drug is completely metabolized, mainly by N-dealkylation. It is excreted in the form of metabolites: with feces - ⅔, with urine - ⅓. The half-life (T 1/2) can be from 3 to 6 hours.
Indications for use
- peripheral circulatory disorders (treatment and prevention) - cold snap in the extremities and night cramps, Raynaud's disease, thromboangiitis obliterans, endarteritis obliterans, diabetic angiopathy, trophic disorders (varicose and trophic ulcers), thrombophlebitis, paresthesias;
- kinetosis - sea and air sickness (prevention);
- labyrinth and vestibular disorders of vascular origin (symptomatic therapy), Meniere's disease.
Contraindications
Absolute:
- age up to 12 years;
- During pregnancy and breastfeeding;
- syndrome of glucose-galactose malabsorption, galactosemia, lactase deficiency;
- celiac disease (celiac disease);
- hypersensitivity to any component of the drug.
With extreme caution, Cinnarizine Sopharma should be prescribed to patients with Parkinson's disease - cinnarizine should be used only when the benefits of therapy significantly outweigh the possible threat of deterioration.
Cinnarizin Sopharma, instructions for use: method and dosage
Cinnarizine Sopharma tablets should be taken orally, after meals, with plenty of liquid.
Recommended dosing regimen for adults and adolescents over 12 years of age:
- peripheral circulatory disorders: 3 times / day, 2-3 tablets (50-75 mg); in the presence of high sensitivity to cinnarizine, the course of treatment is recommended to start with ½ the dose, gradually increasing it; to achieve the desired therapeutic effect, it is required to use the drug constantly and for a long time - for several weeks or several months;
- vestibular disorders, labyrinth disorders: 3 times / day, 1 tablet (25 mg);
- kinetosis: 30 minutes before the upcoming trip, 1 tablet (Cinnarizin Sopharma 25 mg), if necessary, it is allowed to take the drug again in the same dose after 6-8 hours.
The maximum daily dose of Cinnarizine Sopharma is 9 tablets (225 mg).
Side effects
During therapy with the drug, such side effects as gastrointestinal discomfort and drowsiness were most often recorded, usually of a transient nature and stopping with a decrease in the dose.
Other less common side effects of Cinnarizine Sopharma include:
- nervous system: increased fatigue, headache; with prolonged use in high doses, the appearance of extrapyramidal symptoms - increased muscle tone, tremor of the extremities, hypokinesia, imbalance, disorientation, as well as depression, Parkinson's syndrome;
- cardiovascular system: lowering blood pressure;
- digestive system: pain in the epigastric region, dry mouth, dyspepsia; extremely rare - cholestatic jaundice;
- skin and subcutaneous tissue: increased sweating; extremely rare - lupus-like reactions, lichen planus;
- allergic reactions: skin rash;
- others: weight gain.
Overdose
Symptoms of an overdose of cinnarizine may include drowsiness, vomiting, tremors, decreased blood pressure, coma. For the rapid elimination of the drug, gastric lavage and the intake of activated carbon are prescribed, symptomatic treatment is carried out. There is no specific antidote.
special instructions
In order to reduce the risk of possible gastric discomfort caused by taking Cinnarizine Sopharma, it is recommended to take the tablets after meals to reduce irritation of the gastric mucosa.
In patients predisposed to the development of hypotension (lowering blood pressure), blood pressure must be monitored during therapy.
In athletes undergoing doping tests, drug treatment can cause false positives.
In the case of long-term therapy with cinnarizine, monitoring of renal function, liver function and peripheral blood picture should be performed.
Since the drug has an antihistamine effect, it can cause false negative results with skin tests for hypersensitivity. As a result, the drug should be discontinued 4 days before the study.
Influence on the ability to drive vehicles and complex mechanisms
Cinnarizine Sopharma can lead to drowsiness, therefore, during treatment, special care must be taken when driving and operating other complex moving mechanisms.
Application during pregnancy and lactation
Well-controlled clinical studies regarding the safety of the use of Cinnarizine Sopharma in pregnant women have not been conducted, therefore, its use during pregnancy is contraindicated.
Since there is no data on the excretion of cinnarizine in breast milk, therapy with a drug during breastfeeding is contraindicated. If necessary, taking the drug should stop breastfeeding.
Pediatric use
The use of Cinnarizine Sopharma is contraindicated in children under 12 years of age.
Use in the elderly
Persons over 65 years of age who have extrapyramidal disorders in clinical symptoms or family history need constant medical monitoring during treatment.
Drug interactions
- hypertensive drugs: the effect of these drugs decreases;
- vasodilator, nootropic, antihypertensive drugs: the therapeutic effect of these drugs increases;
- sedatives, ethanol: their effects are potentiated.
Analogs
The analogues of Cinnarizin Sopharma are Cinnarizin, Stugeron, Cinnarizin Avexima, etc.
Terms and conditions of storage
Store out of the reach of children, protected from moisture and light, at a temperature not exceeding 25 ° C.
The shelf life is 3 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Cinnarizine Sopharma
Reviews of Cinnarizine Sopharma are in most cases positive. Patients note that the drug, having a low cost, effectively helps to eliminate or significantly weaken the clinical manifestations of peripheral circulatory disorders, and also relieves the symptoms of labyrinth disorders and vestibular disorders.
At the same time, sometimes they indicate an insufficient effect of the drug in the treatment of serious pathologies of the peripheral and cerebral circulation. The disadvantages of Cinnarizin Sopharma also include the presence of side effects, especially drowsiness and pain in the epigastric region.
The price of Cinnarizin Sopharma in pharmacies
The price of Cinnarizin Sopharma 25 mg can be 50–90 rubles. for 50 tablets per pack.
Elena Minkina Doctor anesthesiologist-resuscitator About the author
Education: graduated from the Tashkent State Medical Institute, specializing in general medicine in 1991. Repeatedly passed refresher courses.
Work experience: anesthesiologist-resuscitator of the city maternity complex, resuscitator of the hemodialysis department.
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
